FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Mapi - Pharma's FCF Yield % or its related term are showing as below:
MAPI's FCF Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: -0.13 * Ranked among companies with meaningful FCF Yield % only.
The historical data trend for Mapi - Pharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Mapi - Pharma FCF Yield % Chart
Mapi - Pharma Annual Data
Trend
Dec12
Dec13
Dec14
FCF Yield %
-
-
-
Mapi - Pharma Semi-Annual Data
Dec12
Dec13
Jun14
Dec14
Jun15
FCF Yield %
-
-
-
-
-
Competitive Comparison of Mapi - Pharma's FCF Yield %
For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mapi - Pharma's FCF Yield % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Mapi - Pharma's FCF Yield % falls into.
Mapi - Pharma FCF Yield % Calculation
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Mapi - Pharma's FCF Yield % for the fiscal year that ended in Dec. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mapi - Pharma FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Mapi - Pharma FCF Yield % Related Terms
Thank you for viewing the detailed overview of Mapi - Pharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Mapi - Pharma (Mapi - Pharma) Business Description
Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MAPI has been successfully added to your